The document provides an update on Tekmira Pharmaceuticals, highlighting its focus on RNA interference (RNAi) therapeutics. It discusses the company's pipeline, including drugs targeting cancer, Ebola, Hepatitis B, and alcohol use disorder. The document also covers Tekmira's proprietary LNP delivery technology, partnerships, financial projections, and competitive landscape.
documents/EFTA01197764.pdf
{}